a new molecule for the treatment of schizophrenia is currently being developed and is currently in phase 1 development. this is a new molecule that is designed to leverage the learnings from pimavanserin and hit the nice sweet spot. this is a new molecule that is designed to leverage the learnings from pimavanserin and hit the nice sweet spot. we will continue to position ourselves to leverage an increasingly attractive opportunity set for business development in crn and rare disease.